Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives

• Published in: Therapeutic advances in vaccines and immunotherapy 2024, Vol.12
• Main Authors: Shahzadi, Muqadas, Rafique, Hamad, Waheed, Ahmad, Naz, Hina, Waheed, Atifa, Zokirova, Feruza Ravshanovna, Khan, Humera
• Format: Article
• Language: English
• Subjects: Navigating Global Trends in Cancer Care: Immunotherapy and Precision Diagnostics
• ISSN: 2515-1355; 2515-1363
• DOI: 10.1177/25151355241305856

Using artificial intelligence (AI) to enhance chimeric antigen receptor (CAR)-based therapies’ design, production, and delivery is a novel and promising approach. This review provides an overview of the current applications and challenges of AI for CAR-based therapies and suggests some directions for future research and development. This paper examines some of the recent advances of AI for CAR-based therapies, for example, using deep learning (DL) to design CARs that target multiple antigens and avoid antigen escape; using natural language processing to extract relevant information from clinical reports and literature; using computer vision to analyze the morphology and phenotype of CAR cells; using reinforcement learning to optimize the dose and schedule of CAR infusion; and using AI to predict the efficacy and toxicity of CAR-based therapies. These applications demonstrate the potential of AI to improve the quality and efficiency of CAR-based therapies and to provide personalized and precise treatments for cancer patients. However, there are also some challenges and limitations of using AI for CAR-based therapies, for example, the lack of high-quality and standardized data; the need for validation and verification of AI models; the risk of bias and error in AI outputs; the ethical, legal, and social issues of using AI for health care; and the possible impact of AI on the human role and responsibility in cancer immunotherapy. It is important to establish a multidisciplinary collaboration among researchers, clinicians, regulators, and patients to address these challenges and to ensure the safe and responsible use of AI for CAR-based therapies. Graphical abstract